The U.S. Food and Drug Administration approved a new prescription-strength pain reliever from Vertex Pharmaceuticals on Jan. 30, 2025. Journavx is a non-opioid drug that prevents peripheral nerves ...

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA). The company’s "first-in-class" suzetrigine pain pill ...

The FDA recently approved Journavx for treating acute pain. This approval is tremendously important for Vertex Pharmaceuticals. The biotech company has also received other good news over the last ...

Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III ...

Vertex Pharmaceuticals (NASDAQ ... the company can now add to its list of approved drugs. On Jan. 30, the FDA granted approval for Vertex's pain medication, Journavx. It's a non-opioid treatment ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

Vertex Pharmaceuticals (NASDAQ:VRTX) announced Friday that an expert panel of the EU drug regulator, the European Medicines ...

The US FDA has approved Journavx, a new pain reliever without the risks for addiction or overdose linked to drugs like Vicodin and OxyContin.

When Vijay Sankaran was an MD-PhD student at Harvard Medical School in the mid-2000s, one of his first clinical encounters ...

Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are down about 9% from a peak the stock set in November, despite some highly positive news. The U.S. Food and Drug Administration (FDA) approved ...